Insilico Medicine and Fosun Pharma Announce Strategic Collaboration

Insilico Medicine and Fosun Pharma have announced an important strategic collaboration agreement. The partnership was announced yesterday at the 40th Annual J.P. Morgan Healthcare Conference. The companies will use Insilico's AI driven drug discovery platform to advance the discovery and development of drugs targeting a number of different diseases. The collaboration includes an upfront payment of $13 million plus an equity investment in Insilico Medicine of an undisclosed amount. The collaboration will combine Insilico's end-to-end AI-driven drug discovery platforms and Fosun Pharma's clinical development and commercial expertise to discover and develop a portfolio of novel therapeutics.